Flora Solano-Rivera

Ms. Flora Solano-Rivera

Sanoviv Medical Institute, Playas de Rosarito, Baja California, Mexico

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2022 in Toxins
Verified
Journal Article
Open access
PDF file
KUNAL GARGKUNAL GARG
KUNAL GARG
FVFausto Villavicencio-Aguilar
Fausto Villavicencio-Aguilar
Flora Solano-RiveraFlora Solano-Rivera
Flora Solano-Rivera
Leona GilbertLeona Gilbert
Leona Gilbert
Mycotoxin exposure in humans is primarily assessed through its occurrence in external sources, such as food commodities. Herein, we have developed a direct competitive ELISA to facilitate the detection of aflatoxin B1 (AFB1), deoxynivalenol (DON), fumonisin (FUM B1/B2), ochratoxin A (OTA), and zearalenone (ZEA) in human serum. The analytical validation of the assay followed practices endorsed by the international research community and the EU directive 96/23/EC in order to examine detection capability, recovery, and cross-reactivity. The assay demonstrated a lower limit of quantitation (LLOQ) for AFB1 [0.61 ng/mL (hereon ng/mL = ppb)], DON (19.53 ppb), FUM (4.88 ppb), OTA (19.53 ppb), and ZEA (0.15 ppb). Recovery from human serum for all mycotoxins spanned from 73% to 106%. Likewise, the specificity for monoclonal antibodies against cross-reactant mycotoxins ranged from 2% to 11%. This study compares the LLOQ and recovery values with commercial and emerging immuno-based methods for detecting mycotoxins in foodstuffs. The LLOQ values from the present study were among the lowest in commercial or emerging methods. Despite the differences in the extraction protocols and matrices, the recovery range in this study, commercial tests, and other procedures were similar for all mycotoxins. Overall, the assay detected AFB1, DON, FUM, OTA, and ZEA in human serum with excellent accuracy, precision, and specificity.

12 December 2025 in Pathogens
Verified
Journal Article
Open access
PDF file
KUNAL GARGKUNAL GARG
KUNAL GARG
FVFausto Villavicencio-Aguilar
Fausto Villavicencio-Aguilar
Flora Solano-RiveraFlora Solano-Rivera
Flora Solano-Rivera
Leona GilbertLeona Gilbert
Leona Gilbert
Tick bites acquired in the northern or southern hemisphere can transmit microbes that may cause illness. The most prevalent infection is Lyme borreliosis (LB), with all proven cases to date having been acquired in the northern hemisphere. The existence of endemic LB in Australia has not been proven explicitly, and there is uncertainty concerning the cause of “Lyme-like” disease (LLD) in Australia. As many tick-borne diseases (TBDs) are diagnosed by serology, validated assays for use in both the northern and southern hemispheres are required. Using a multiplex enzyme-linked immunosorbent assay (TICKPLEX®), two independent laboratories tested a total of 53 well-characterized reference sera that consisted of 33 samples from northern hemisphere patients with confirmed tick-borne disease (TBD) and 20 randomly selected sera from Australian patients with suspected TBDs, presenting with or without LLD. Antibody responses to multiple microbial antigens from causative agents of TBDs were found. High concordance between laboratories was demonstrated on this small set of samples. The results obtained provide the basis for further evaluation of TICKPLEX® on a larger number of samples from Australian patients with suspected TBDs. These findings should be considered preliminary, providing proof-of-concept evidence that warrants validation in larger, clinically diverse cohorts.

3 December 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
KUNAL GARGKUNAL GARG
KUNAL GARG
FVFausto Villavicencio-Aguilar
Fausto Villavicencio-Aguilar
Flora Solano-RiveraFlora Solano-Rivera
Flora Solano-Rivera
Leona GilbertLeona Gilbert
Leona Gilbert
Tick bites acquired in the northern or southern hemispheres can transmit microbes that may cause illness. The most prevalent infection is Lyme Disease, with all proven cases to date having been acquired in the northern hemisphere. The existence of endemic Lyme disease (LD) in Australia has not been proven explicitly, and there is uncertainty concerning the cause of “Lyme-like” disease (LLD) in Australia. As many tick-borne infections (TBIs) are diagnosed by serology, validated assays for use in both the northern and southern hemispheres are required. Using a multiplex enzyme-linked immunosorbent assay (TICKPLEX®), two independent laboratories tested a total of 53 well-characterized reference sera that consisted of 33 samples from northern hemisphere patients with confirmed tick-borne disease (TBD) and 20 randomly selected sera from Australian patients with suspected TBIs, presenting with or without LLD. Antibody responses to multiple microbial antigens from causative agents of TBDs were found. High concordance between laboratories was demonstrated on this small set of samples. The results obtained provide the basis for further evaluation of TICKPLEX® on a larger number of samples from Australian patients with suspected TBIs.